Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 8Recruiting 2Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Keratosis, Actinic 1

Interventions

Nivolumab 18Ipilimumab 16pembrolizumab 15Cyclophosphamide 13trametinib 9Radiotherapy 8dabrafenib 6Interleukin-2 6sargramostim 5fludarabine phosphate 5aldesleukin 5Vemurafenib 5Peripheral Blood Stem Cell Transplantation 5Fluorouracil 5130-nm albumin-bound paclitaxel 5fludarabine 4Radiosurgery 4Melphalan 4Celecoxib 4encorafenib 3durvalumab 3binimetinib 3avelumab 3Vorinostat 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Leucovorin 3Granulocyte-Macrophage Colony-Stimulating Factor 3Cytarabine 3Capecitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Solutions × Dermatologic × Clear all
NCT03024060 2017-11-07

Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

DUSA Pharmaceuticals, Inc.

Phase 3 Withdrawn
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡